Observational Study for Lung Cancer Patients Treated With Nivolumab

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1462 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-10-01

Study Completion Date

2020-12-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will describe the characteristics of patients initiating nivolumab treatment for lung cancer and their outcomes over 3 years in France

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy

NCT04500535

Lung Cancer

COMPLETED

Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program

NCT02933346

Non-small Cell Lung Cancer Nivolumab Long-term Adverse Effects

COMPLETED

Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France

NCT06735781

Non-small Cell Lung Cancer (NSCLC)

COMPLETED

Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer

NCT04858204

NSCLC

COMPLETED

Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs

NCT02350764

Advanced Stage Non-small Cell Lung Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lung Cancer patients in France

Lung Cancer patients treated by nivolumab in real life condition in France from October 2016 to October 2017

Non-Interventional

Intervention Type OTHER

Non-Interventional

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-Interventional

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female: 18 age at the time of nivolumab initiation
* Pathologically confirmed diagnosis of lung cancer
* Patient initiating nivolumab :therapeutic decision to initiate nivolumab must be taken by the physician prior to enrolling a patient in the study